Covista Inc. Reports Higher Revenue, Operating Income, Net Income, and Diluted EPS Across the Twelve-Month Period Versus the Prior-Year Comparative, With Each Line Remaining Profitable Year Over Year

Bottom line

- Revenues for the twelve months ended June 30, 2026 came in at $1,954,085,000 USD, higher than the prior-year comparative of $1,788,290,000 USD for the twelve months ended June 30, 2025, with the top line remaining positive across both reported windows. - Operating Income (Loss) for the twelve-month period was $383,376,000 USD, higher than the prior-year figure of $341,542,000 USD, keeping operations in a profit position on a year-over-year basis. - Net Income (Loss) Attributable to Parent registered $251,566,000 USD for the twelve months ended June 30, 2026, higher than the $237,065,000 USD reported for the twelve months ended June 30, 2025, and the bottom line stayed profitable in both windows. - Earnings Per Share, Diluted was $7.04 per diluted share USD/SHARES for the twelve-month period, higher than $6.18 per diluted share USD/SHARES in the prior-year comparative, with diluted EPS remaining positive across the two windows. Reporting-period identity and source scope: this analysis covers Covista Inc. (ticker CVSA, CIK 0000730464) as disclosed in its 10-K filing for fiscal period period-ended-2026-06-30, filed under accession 0001104659-26-092044. The source is the Annual Report on Form 10-K itself, and the figures above are drawn from the consolidated income-statement presentation that reports the twelve months ended June 30, 2026 alongside the the twelve months ended June 30, 2025 comparative.

The filing's structural anchors that frame these results include Item 8 (Financial Statements and Supplementary Data), Item 7A (Quantitative and Qualitative Disclosures About Market Risk), and Item 9A (Controls and Procedures). The forward-looking-statements disclosure that runs across the Business, Risk Factors, and MD&A sections is explicitly cross-referenced to Item 1A, and the remainder of the Annual Report on Form 10-K is organized around Item 10, Item 13, and the related items listed in the catalog.

Analyst inference: the authorized year-over-year pattern across Revenues, Operating Income (Loss), Net Income (Loss) Attributable to Parent, and Earnings Per Share, Diluted is uniformly higher in the current twelve-month window than in the prior-year comparative, and each line retained a profit position in both windows. The filing evidence does not attribute this change to any single cause.

Counter-evidence and unknowns: the filing evidence does not contain a peer or industry comparison, so any cross-company read on margin, growth, or share would be unsupported. The filing evidence contains no peer or industry comparison. Segment-level revenue and enrollment detail for Chamberlain, Walden, and the Medical and Veterinary segment are referenced narratively in the filing but are not part of this section's fact catalog, so they are not quantified here. Operating, investing, and financing cash flow figures, capital expenditure, and share-repurchase lines appear elsewhere in the source record for later sections and are outside this section's scope. All values cited are presented as reported in the filing; no restatement, normalization, or pro-forma adjustment has been applied.

Financial performance

- Revenues for Covista Inc. during the twelve months ended June 30, 2026 came in at $1,954,085,000 USD, compared with $1,788,290,000 USD in the twelve months ended June 30, 2025. The authorized direction is an increase, and the transition is positive year on year; readers comparing the two twelve-month windows will see a higher top line in the current period than in the prior period.

No cause-and-effect explanation is authorized for that lift, and the source narrative does not attribute the change to any single driver. - Operating Income (Loss) for the same twelve-month period was $383,376,000 USD versus $341,542,000 USD a year earlier. Both readings sit on the profit side of the ledger, so the authorized transition is profit to profit, and the authorized direction is higher operating income in the current window than in the prior one.

- Net Income (Loss) Attributable to Parent reached $251,566,000 USD in the twelve months ended June 30, 2026 against $237,065,000 USD in the twelve months ended June 30, 2025. The authorized direction is an increase, the transition is profit to profit, and the magnitude of the current reading is above that of the prior-year comparative. The filing evidence does not single out a cause, and the segment-level bridge is not disclosed for this dimension in the quoted materials.

18 per diluted share USD/SHARES for the twelve months ended June 30, 2025, with the authorized direction an increase and the transition profit to profit. Reported management commentary in the quoted evidence focuses on program descriptions rather than per-share walkthroughs, so no analyst-style bridge between the two EPS readings is supplied. - Management context: the quoted narrative describes Chamberlain's pre-licensure BSN, RN-BSN, MSN, DNP, MPH, MSW, and MPAS programs, the multi-start admissions calendar, and Walden's professional-learner positioning.

Those passages describe the educational portfolio and admissions cadence; they do not quantify enrollment, pricing, occupancy, or mix changes that would explain the year-on-year movement in revenue, operating income, net income, or diluted EPS. - Analyst inference is therefore limited. The only year-over-year facts authorized for this section are the directional and transition calls already listed, and the machine-owned statement applies where a reader might expect a driver: The filing evidence does not attribute this change to any single cause..

Likewise, the filing evidence carries no peer or industry comparison, so any cross-company framing should be deferred: The filing evidence contains no peer or industry comparison.. Segment-level detail is also absent in the quoted materials for revenue and for the income measures: The filing evidence does not disclose segment-level detail for this dimension.. - Counter-evidence and unknowns: no item in the quoted source narrative challenges the authorized direction for revenues, operating income, net income, or diluted EPS; the only caveat is that none of these directions is paired with an authorized cause.

Out-year guidance is not supplied in the quoted evidence, so any forward statement about the twelve months ended June 30, 2026 would be speculative; this article reports only the figures the filing itself discloses.

Operating drivers and segments

- The filing reports results at the consolidated level only. The narrative names three reportable segments — Chamberlain, Walden, and Medical and Veterinary (AUC, RUSM, and RUSM) — but the FACT catalog exposes no segment-level revenue, operating income, or margin figures for any of them. - For the twelve-month period covered by period-ended-2026-06-30 (filing 10-K, accession 0001104659-26-092044, CIK 0000730464, ticker CVSA), the consolidated top line stands at $1,954,085,000 versus the prior-year comparative of $1,788,290,000.

That represents an increase at the consolidated level; the segment mix behind it is not disclosed in this catalog. - Consolidated operating income tracks a similar pattern: $383,376,000 against $341,542,000, an increase that keeps the consolidated segment above an operating loss in both windows. - No peer or industry comparison is supplied in the quoted evidence, so any read on segment-level margin trends relative to other for-profit or nonprofit postsecondary educators is unsupported here.

- The narrative frames Covista as "America's largest healthcare educator," built around four strategic principles — operational excellence, platform extension, employer integration, and technology focus. It uses these principles as the explanation for forward direction, not as quantified segment drivers. - Chamberlain is described as offering pre-licensure BSN, post-licensure BSN, MSN, DNP, MPH, MSW, and MPAS programs across its campuses and online channels, with an evening/weekend BSN option launched at select campuses and a separate online BSN launch cited in the quoted text.

Walden is positioned around degree and certificate programs in nursing, education, counseling, business, information technology, psychology, public health, social work, human services, public administration and public policy, and criminal justice. The Medical and Veterinary segment is described through AUC, RUSM, and RUSVM. - Management cautions that forward-looking statements are subject to risks disclosed in "Risk Factors" and elsewhere, but it does not tie those risks to specific segment revenue or margin movements.

- The consolidated revenue and operating income comparisons above are the only quantified direction statements the catalog authorizes. No segment-level growth narrative can be supported from the filing evidence, and no single-cause story (pricing, enrollment mix, online mix, acquisitions, cost pressure) is authorized for the consolidated figures either — the cause is not stated in the quoted material. The filing evidence does not attribute this change to any single cause.

The filing evidence contains no peer or industry comparison.

Cash flow and capital

- Across the twelve-month window, Net Cash Provided by (Used in) Operating Activities shifted higher than the prior-year comparative, moving from a positive base to a larger positive figure; both the current period and the prior-year period produced cash from operations rather than consuming it. - Net Cash Provided by (Used in) Investing Activities worsened compared with the prior-year comparative, with both periods running negative and the current period showing a deeper outflow than the prior year. - Net Cash Provided by (Used in) Financing Activities improved relative to the prior-year comparative, with both periods negative and the current period showing a smaller outflow than the prior year.

- Within investing outflows, Payments to Acquire Property, Plant, and Equipment rose versus the prior-year comparative; the current period's capex figure is positive, as is the prior year's, indicating that the company funded a larger property, plant, and equipment program this year than last. - Payments for Repurchase of Common Stock climbed higher than the prior-year comparative; both periods recorded positive repurchase outflows, signalling that share buybacks were a larger use of cash this year than last. - The balance sheet at period-end carried Cash and Cash Equivalents, at Carrying Value, alongside Long-term Debt, Excluding Current Maturities; both line items are positive, so the company ended the period holding cash while also carrying non-current debt obligations beyond the current portion.

- The combined picture is one in which operating cash generation expanded while the company simultaneously increased both its capital spending and its share repurchase activity; the financing outflow narrowed at the same time, leaving investing absorbing more cash year over year. - The filing evidence does not attribute this change to any single cause. - The filing does not break out the parent company, AUC, or RUSM operations separately for any of these cash-flow or balance-sheet line items in the cited note, so segment-level detail for this dimension is not disclosed by the evidence.

- The filing evidence does not disclose segment-level detail for this dimension. - The filing evidence contains no peer or industry comparison.

Peer and historical context

- Reported facts versus the prior comparative for the twelve-month window show a uniformly stronger picture across every authorized headline measure, with revenues, operating income, net income, and operating cash flow each registering an authorized increase on a year-over-year basis (Revenues, Operating Income (Loss), Net Income (Loss) Attributable to Parent, and Net Cash Provided by (Used in) Operating Activities each carrying an authorized direction of increase from the twelve months ended June 30, 2025 to the twelve months ended June 30, 2026).

- The prior comparative was already profitable at the operating and net income lines, so the authorized transition in both cases is profit to profit, indicating a wider margin profile rather than a swing from loss into profit (Operating Income (Loss) and Net Income (Loss) Attributable to Parent each authorized as profit to profit). - Operating cash flow moved higher on a year-over-year basis while remaining positive, reinforcing the read that the topline and earnings gains were accompanied by stronger cash generation rather than working-capital deterioration (Net Cash Provided by (Used in) Operating Activities authorized as increase with current positive, prior positive).

- The filing context characterizes Covista Inc. as an operator of multiple postsecondary brands, including medical, veterinary, nursing, and broader online higher-education programs, and the narrative emphasizes competitive pressure from public universities, community colleges, and other for-profit and non-profit online providers, with the nursing market described as highly fragmented across pre-licensure and post-licensure segments. - Because the filing evidence contains no externally sourced peer figures or industry benchmarks, any cross-issuer read (such as how this topline compares with named peers in the same window) cannot be supported from the filing itself.

- Without comparable figures from named peers or third-party industry datasets in this filing, the section cannot validate that the authorized increase pattern outpaces the sector; readers should weight the year-over-year directional read more heavily than any implied peer-relative claim. - The authorized relations stop at directional movement; nothing in the catalog authorizes a cause, so margin expansion, pricing actions, enrollment mix, or cost discipline cannot be assigned to the gap even in qualified language. - Readers comparing this snapshot with other issuers' filings can pair this read with a quick ROI Calculator check on the operating-income-to-revenue relationship they observe across windows, without using that tool to assert a peer-relative ranking.

Scenario analysis

- Reported figure observed: Revenues for the twelve-month period described in this filing, paired with Net Income (Loss) Attributable to Parent over the same window. - Reported figure observed: Prior-year Revenues for the comparative twelve-month period, paired with the prior-year Net Income (Loss) Attributable to Parent. - Analyst inference: The base case tracks the only year-over-year relations the catalog pre-authorizes — Revenues increasing versus the prior-year window and Net Income (Loss) Attributable to Parent increasing versus the prior-year window, with each transition keeping a profit rather than flipping to a loss. Operating Income (Loss), Earnings Per Share Diluted, and Net Cash Provided by Operating Activities all share the same authorized direction of increase across the two windows, while Net Cash Provided by (Used in) Financing Activities and the two capital-spending lines move in directions the catalog also pins in advance. - Counter-evidence: The catalog does not authorize any cause-and-effect claim about why these headline figures rose; the filing narrative itself focuses on market structure, accreditation, and competitive positioning rather than on a named earnings driver. - Unknowns: Detail on regulation changes, accreditation loss scenarios, or demand-side shocks that could compress either line is not disclosed in the narrative.

- Reported figure observed: The authorized transition keeps the company profitable on the top and bottom lines across both reporting windows, so the upside path does not require a return to profitability — it requires extending it. - Analyst inference: Sustained tuition pricing power at Chamberlain and Walden, continued accreditation standing across BSN, MSN, DNP, MPH, MSW, and ARC-PA programs, and stable new-enrollment flow at the pre-licensure and post-licensure levels would together support the directional uplift the catalog already encodes for Revenues and Net Income (Loss) Attributable to Parent, holding the base relationships in place. - Counter-evidence: Walden competes with traditional public and private non-profit institutions and for-profit schools, and public universities can charge lower tuition because of state subsidies and government grants — a structural margin headwind that the filing evidence does not quantify. - Unknowns: Specific enrollment counts, tuition rate changes, or capacity expansions at either segment are not disclosed at the line-item level; The filing evidence does not disclose segment-level detail for this dimension. applies to either side of the upside path.

- Reported figure observed: Both authorized relations describe a positive year-over-year change, so the downside path is a softening of that uplift rather than an absolute decline in the catalog's own terms — The filing evidence does not attribute this change to any single cause. governs any attribution. - Analyst inference: Loss of accreditation status at Chamberlain or Walden, an adverse change in NCLEX-RN or other licensure pipelines, or pricing compression as more campus-based institutions launch online programs could each pressure the directional margins the catalog anchors, and Net Cash Provided by (Used in) Investing Activities is already authorized to decrease across the two windows — a capital-spending pattern that constrains re-investment flexibility if demand weakens. - Counter-evidence: Chamberlain holds the largest pre-licensure program in the U.S. and Walden is one of the leading doctoral and master's conferrers in nursing, public health, and adjacent fields, which argues for stickiness in the enrollment base. - Unknowns: New-student enrollment volumes by school, regulatory actions by CCNE, NLN CNEA, CEPH, CSWE, or ARC-PA, and the supply-and-demand balance in medical and veterinary education are not disclosed in item-by-item form; peer and industry benchmarking is also absent per The filing evidence contains no peer or industry comparison..

Risks and what to watch

- Reported results and prior-year comparatives, for the twelve-month period and the prior-year twelve-month window, sit on opposite sides of the same simple profitability story: Revenues and Net Income (Loss) Attributable to Parent were both positive in each window, and both moved higher year over year, with the current twelve-month period the larger figure in each pair. The machine-owned ledger authorizes no cause for that movement, so any attempt to explain the lift — pricing, mix, enrollment ramp, cost discipline — is not supported by the filing evidence, and is replaced here by The filing evidence does not attribute this change to any single cause..

- The principal counter-evidence inside the filing narrative concerns the operating environment, not the headline numbers. The source narrative frames the business around a supply/demand imbalance for medical and veterinary education enrollment capacities, with prospective student and employer demand expected to continue to outpace supply of capacity. That is a structural-growth argument, not a reported metric; if demand softens, the implied runway for further revenue and net income growth narrows even though the twelve-month window itself shows an increase on both lines.

- Accreditation risk is the most concrete qualitative risk the narrative surfaces. S. state standards).

Loss or non-renewal of any of these would constrain enrollment capacity, which is the lever the supply/demand thesis depends on. - Segment-level detail, peer benchmarking, and any explicit driver decomposition are not disclosed in the evidence available to this section. Operating Income (Loss) and Earnings Per Share, Diluted both read as profit-to-profit transitions at higher year-over-year levels per the authorized comparison ledger, but the filing does not attribute the change to a single cause.

The filing evidence contains no peer or industry comparison. The filing evidence does not disclose segment-level detail for this dimension. - Counter-evidence the reader should weigh against the upbeat top line: the narrative is rich on accreditation lists and capacity language but thin on quantitative margin, cost, or capital-allocation disclosures in this section's source material, so the headline profit increase cannot yet be cross-checked against segment profitability, capex intensity, or share-repurchase behavior in any way the catalog supports.

- Metrics to watch in the next twelve-month window: whether Revenues continue to expand against the prior twelve-month comparative, whether Net Income (Loss) Attributable to Parent continues to expand against the prior twelve-month comparative, any change in accreditation status — particularly movements of programs off Accreditation-Provisional or initial status — that would alter the supply/demand capacity story the narrative relies on, and disclosure of segment-level results that would let readers test whether the top-line lift is broad-based or concentrated, given that such detail is not visible in the current evidence.

Readers modeling the trajectory in their own work can sanity-check assumptions with the ROI Calculator, though it does not substitute for the segment and accreditation disclosures the filing has not yet provided.